Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Clin Pharm Ther ; 34(3): 337-44, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19646080

ABSTRACT

PURPOSE: Empirical use of intravenous (IV) itraconazole (ITZ) for febrile neutropenic patients has recently been introduced in Korea. This study was designed to investigate the population pharmacokinetics (PK) of IV-ITZ. METHODS: Sparse PK data were collected from febrile neutropenic patients undergoing empirical ITZ therapy at 200 mg/day after loading doses. NONMEM (Version. 5.1.1) was used to estimate population PK parameters. RESULTS: Forty-two patients were enrolled in the study. Mean population CL and V of IV-ITZ were 10 L/h and 1050 L, respectively. Body weight was the only contributing covariate of CL. The median simulated trough concentration of ITZ after 10 days was predicted to be about 700 ng/mL. CONCLUSIONS: In this study, we explored the population PK profile of ITZ given in IV formulation. We found that the current dosage regimen of IV-ITZ (200 mg/day) was appropriate to obtain therapeutic trough concentrations for neutropenic patients in Korea.


Subject(s)
Antifungal Agents/pharmacokinetics , Fever/drug therapy , Itraconazole/pharmacokinetics , Neutropenia/drug therapy , Adolescent , Adult , Antifungal Agents/administration & dosage , Body Weight , Dose-Response Relationship, Drug , Female , Fever/etiology , Humans , Infusions, Intravenous , Itraconazole/administration & dosage , Korea , Male , Middle Aged , Neutropenia/etiology , Nonlinear Dynamics , Prospective Studies , Young Adult
2.
Transpl Infect Dis ; 11(5): 413-23, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19708893

ABSTRACT

OBJECTIVES: To evaluate the incidence of infectious complications after receiving alemtuzumab as part of a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in Korean patients. METHODS: From November 2004 to January 2006, 12 patients who received alemtuzumab-based conditioning regimens for allogeneic HSCT were evaluated retrospectively until death or until the end of the follow-up in July 2007; they were compared with 18 patients who received rabbit anti-thymocyte globulin (ATG)-containing conditioning regimens from January 2002 to January 2006. RESULTS: Post-engraftment infections occurred more frequently in the alemtuzumab recipients than in the ATG recipients; the mean number of infections, excluding cytomegalovirus (CMV) infections, per patient during the follow-up period was 2.6+/-1.4 vs. 1.0+/-0.8 (P=0.003), respectively. Although there was no statistical difference in the cumulative incidence of CMV infection between the 2 groups (91.7% vs. 55.6%, P=0.381), the alemtuzumab recipients had a higher incidence of CMV diseases (41.6% vs. 0%, P=0.0006) and a higher recurrence rate of CMV infection (90.0% vs. 27.3%, P=0.008) than did the ATG recipients, irrespective of the dose of alemtuzumab. Hemorrhagic cystitis (HC) (66.7% vs. 16.7%, P=0.009) and BK virus-associated HC (41.7% vs. 5.6%, P=0.026) developed more frequently in the alemtuzumab recipients. The all-cause mortality rate was not significantly different between the alemtuzumab and the ATG recipients (75% vs. 55.6%, P=0.28). CONCLUSION: Alemtuzumab recipients had a high incidence of CMV disease as well as BK virus-associated HC compared with the ATG recipients. The dose of alemtuzumab should be tailored to patients' risk; in addition, the implementation of the appropriate prophylaxis for CMV and early detection strategies for BK virus are recommended.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antibodies, Neoplasm/adverse effects , Antilymphocyte Serum/adverse effects , Cystitis , Cytomegalovirus Infections/epidemiology , Hematopoietic Stem Cell Transplantation , Immunologic Factors/adverse effects , Adolescent , Adult , Aged , Alemtuzumab , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antibodies, Neoplasm/therapeutic use , Antilymphocyte Serum/therapeutic use , BK Virus/isolation & purification , Cystitis/epidemiology , Cystitis/virology , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/virology , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Immunologic Factors/therapeutic use , Incidence , Male , Middle Aged , Polyomavirus Infections/diagnosis , Polyomavirus Infections/epidemiology , Polyomavirus Infections/virology , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , Transplantation, Homologous/adverse effects , Treatment Outcome , Tumor Virus Infections/diagnosis , Tumor Virus Infections/epidemiology , Tumor Virus Infections/virology , Young Adult
3.
Acta Virol ; 50(4): 263-8, 2006.
Article in English | MEDLINE | ID: mdl-17177612

ABSTRACT

Short interfering RNAs (siRNAs), namely siUL54-1 and siU54-2 targeting UL54 (DNA polymerase) gene, and siUL97-1 and siUL97-2 targeting UL97 (phosphotransferase) gene, were used to inhibit respective genes of Human cytomegalovirus (HCMV) and consequently the virus infection process in human foreskin fibroblast (HFF) cultures. The virus infection was monitored by cell morphology (CPE), levels of UL83 and IE86 mRNAs, and virus antigen. The results showed that siUL97-2 remarkably inhibited viral CPE while other siRNAs were less inhibitory. The siRNAs reduced the levels of UL83 mRNA but not that of IE86 mRNA; again, siUL97-2 was most inhibitory. Particularly, siUL97-2 reduced the UL83 mRNA level 14, 19, 203, and 37 times at 24, 48, 72, and 96 hrs post infection (p.i.), respectively. When tested for the effect on viral antigen by immunofluorescent assay (IFA), UL97-2 exerted a marked inhibition. These results demonstrate the effectiveness of siRNAs against experimental HCMV infection and indicate their therapeutic potential.


Subject(s)
Cytomegalovirus/genetics , Cytomegalovirus/physiology , DNA-Directed DNA Polymerase/genetics , Phosphotransferases (Alcohol Group Acceptor)/genetics , RNA Interference , RNA, Small Interfering/pharmacology , Viral Proteins/genetics , Antigens, Viral/analysis , Antiviral Agents/pharmacology , Cell Line , Cytomegalovirus/drug effects , Cytopathogenic Effect, Viral , DNA-Directed DNA Polymerase/biosynthesis , Fibroblasts/virology , Fluorescent Antibody Technique, Direct , Gene Expression Regulation, Viral/drug effects , Humans , Phosphotransferases (Alcohol Group Acceptor)/biosynthesis , RNA, Messenger/analysis , RNA, Viral/analysis , Viral Proteins/biosynthesis , Virus Replication/drug effects , Virus Replication/genetics
5.
Bone Marrow Transplant ; 34(6): 497-504, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15286689

ABSTRACT

We reviewed 242 allogeneic hematopoietic stem cell transplantation (HSCT) recipients retrospectively over a 2-year period (January 1998-December 1999) in order to analyze the characteristics and assess the outcomes of infectious complications in patients after HSCT in Korea. Bacteria were the major pathogens before engraftment, and viral and fungal infections predominated during the post-engraftment period. Varicella zoster virus was the most common viral pathogen after engraftment. Cytomegalovirus disease occurred mainly in the late-recovery phase. The frequency of mold infection was higher than that of yeast. There was a relatively high incidence of tuberculosis (3.0%) and Pneumocystis carinii pneumonia (6.5%). One case of death by measles confirmed by autopsy was also noted. Overall, cumulative mortality was 43% (104/242), and 59.6% of these deaths (62/104) were infection-related. Allogeneic HSCT recipients from unrelated donors were prone to infectious complication and higher mortality than those from matched sibling (17/39 (43.6%) vs 45/203 (22.2%), respectively; P<0.01; odd ratio 2.5; 95% confidence interval 1.2-5.1). As infection was the main post-HSCT complication in our data, more attention should be given to the management of infections in HSCT recipients.


Subject(s)
Bacterial Infections/epidemiology , Infections/epidemiology , Stem Cell Transplantation , Virus Diseases/epidemiology , Adolescent , Adult , Female , Humans , Korea , Leukemia/therapy , Lymphoma/therapy , Male , Middle Aged , Mycoses/epidemiology , Myelodysplastic Syndromes/therapy , Retrospective Studies , Stem Cell Transplantation/adverse effects , Stem Cell Transplantation/mortality , Survival Analysis , Treatment Outcome
8.
Environ Manage ; 21(2): 225-32, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9008073

ABSTRACT

/ This study examines whether or not wilderness visitors'attitudes toward wilderness are related to the quality of the wilderness thathas been visited. From three Ontario, Canada, provincial parks (Algonquin,Killarney, and Quetico), a sample of 540 wilderness campers was randomlyselected from a total of 138,317 campers. People sampled ranged in age from15 to 75 years with a mean of slightly over 37. They were highly educated. Amajority of them resided in urban or suburban areas. Significant correlationsbetween visitors' levels of wilderness attitudes and wilderness qualitywere found. However, wilderness quality evaluated by wilderness visitors(subjective quality) did not agree with that evaluated by the wildernessmanagers (objective quality).KEY WORDS: Wilderness; Attitudes; Subjective quality; Objectivequality

SELECTION OF CITATIONS
SEARCH DETAIL
...